Recursion Pharmaceuticals, Inc.RXRXNASDAQ
Loading
P/E Ratio: Premium ValuationElevated
Percentile Rank100
Studio
Year-over-Year Change

Price-to-earnings ratio

Latest
-2.84
↑ 83% vs avg
Percentile
P100
Near historical high
Streak
2 yr
Consecutive growthElevated
Average
-16.63
Historical baseline
PeriodValueYoY Change
2025-2.84+29.0%
2024-4.00+36.0%
2023-6.25-10.5%
2022-5.65+63.9%
2021-15.64+54.4%
2020-34.30+28.1%
2019-47.73-